....Although the study by Demeestere et al3
was unable to demonstrate ovarian protection with GnRHa during
chemotherapy in patients with lymphoma, this was an underpowered and
exploratory analysis of a study in which both control and experimental
arm patients received hormonal treatment and in which the end point was
flawed. Hence, these results should be considered as exploratory and do
not refute findings from well-designed large RCTs on this topic.

Although
embryo or oocyte cryopreservation is the first choice for fertility
preservation, GnRHa during chemotherapy remains an option for women
interested in preserving ovarian function and fertility.